Creo Ebitda from 2010 to 2024
| CREO Stock | 16.63 0.50 3.10% |
EBITDA | First Reported 2014-01-31 | Previous Quarter -10.5 M | Current Value -11.8 M | Quarterly Volatility 5.1 M |
Check Creo Medical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Creo Medical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.6 M, Interest Expense of 420 K or Selling General Administrative of 42.5 M, as well as many indicators such as . Creo financial statements analysis is a perfect complement when working with Creo Medical Valuation or Volatility modules.
Creo | Ebitda |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Creo Stock Analysis
When running Creo Medical's price analysis, check to measure Creo Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Creo Medical is operating at the current time. Most of Creo Medical's value examination focuses on studying past and present price action to predict the probability of Creo Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Creo Medical's price. Additionally, you may evaluate how the addition of Creo Medical to your portfolios can decrease your overall portfolio volatility.